← Leaderboards
Paul Daniel Hoeprich
Loyola University Chicago
$1,098,448
Attributed
$3,295,345
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $679.5K · FY2011–15$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,295,345 · 1
By mechanism
R01$3,295,345 · 1
Top collaborators
- Adam Driks5 shared
- Amy Rasley5 shared
Most similar at Loyola University Chicago
Same institution · by research overlap
- Adam Driks$3,097,278
- Adriano Marchese$8,579,198
- Amy Rasley$3,057,071
- Elizabeth J Kovacs$23,448,857
Others in their field
Top investigators on “Anthrax Disease”
- Laurence Lemiale · Emergent Product Development Gaithersbur$61,222,506
- Daniel F. Hoft · Saint Louis University$26,271,892
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Donald S. Burke · Johns Hopkins University$21,607,962
- Michael E. Johnson · University Of Illinois At Chicago$19,502,736
- Alan Thomas Johnson · Hawaii Biotech, Inc.$17,292,079
Research focus
Anthrax DiseaseAntibodiesAntigensApolipoproteinsBacillus AnthracisBacillus Anthracis SporeBaseBinding (Molecular Function)BiologicalCapsid ProteinsCold ChainsDoseDrug FormulationsEngineeringEpitopesEscherichia ColiEventHomologous GeneImmune ResponseImmune SystemImmunofluorescence MicroscopyInbred Balb C MiceIn VivoAdjuvant
Grant awards (5)
A novel anti-spore nasal vaccine for protection from anthrax$663,922
R01 · FY2015 · AI
A novel anti-spore nasal vaccine for protection from anthrax$663,922
R01 · FY2014 · AI
A novel anti-spore nasal vaccine for protection from anthrax$624,087
R01 · FY2013 · AI
A novel anti-spore nasal vaccine for protection from anthrax$663,922
R01 · FY2012 · AI
A novel anti-spore nasal vaccine for protection from anthrax$679,492
R01 · FY2011 · AI